What is it about?
The incidence of colonization and infection with vancomycin resistant enterococci (VRE) is on the increase. This paper comprehensively examines the epidemiology, prevention, and treatment of VRE infections in hematopoietic stem cell transplant (HCT) recipients. This includes an understanding of the role of the environment, alteration in the gastrointestinal microbiome, the possible role of preemptive therapy, and the complexities of definitive antimicrobial therapy.
Featured Image
Why is it important?
VRE infection is an increasingly important cause of morbidity and mortality in HCT recipients.
Perspectives
This review comprehensively ties together a large number of evolving aspects of VRE and HCT and provides a basis for effectively dealing with the problem. This exercise made the issue more understandable to me, allowing me to more effectively approach to the problem - a benefit that I believe the reader will similarly benefit.
Stan Deresinski
Stanford University
Read the Original
This page is a summary of: Vancomycin-resistant enterococcus infection in the hematopoietic stem cell transplant recipient: an overview of epidemiology, management, and prevention, F1000Research, January 2018, Faculty of 1000, Ltd.,
DOI: 10.12688/f1000research.11831.1.
You can read the full text:
Contributors
The following have contributed to this page